HONG KONG – Looking to continue morphing from a maker of active pharmaceutical ingredients (APIs) to a key biologic drug developer and manufacturer, Zhejiang Hisun Pharmaceutical Co. Ltd. has bought the rights to a targeted therapy for epithelioma in China from U.S. biotech company Nascent Biotech Inc.